Bayer's Supreme Court Victory Sets the Stage for a July 9 Settlement Verdict That Will Test the Rally
30.06.2026 - 02:51:44 | boerse-global.de
The coming week will determine whether Bayer’s recent surge has genuine staying power. On July 9, a Missouri court is scheduled to deliver final approval for a $7.25 billion glyphosate settlement — a decision that could remove one of the heaviest legal clouds hanging over the stock. That hearing follows a landmark Supreme Court ruling on June 25, which ruled that federal preemption overrides state-law claims about inadequate cancer warnings on glyphosate. The twin legal developments have already lit a fire under the shares: Bayer gained nearly 19% in the seven days after the high court’s decision, pushing the stock to 45.82 euros. Since then, profit-taking has trimmed the move, with the last trade at 45.39 euros — a 2.6% pullback that has done little to cool the technical heat. The relative strength index stands at 76, deep in overbought territory, warning that a short-term consolidation may be overdue.
The rally’s foundation, however, rests on more than legal relief. Bayer’s pipeline is slowly taking shape, with the oral Factor XIa inhibitor Asundexian emerging as the most important catalyst on the operational side. The FDA accepted the drug’s application in May under priority review, China followed with its own priority designation, and the European Medicines Agency has kicked off central assessment — making this the first filing for a Factor XIa inhibitor in Europe. Asundexian is designed to prevent ischemic strokes, a market where the addressable opportunity is enormous: strokes are the second-leading cause of death in Europe, affecting roughly 10 million survivors. The drug will have to compete with Milvexian, a direct rival being developed by Bristol Myers Squibb and Johnson & Johnson, but Bayer holds a regulatory lead.
What complicates the picture is the sheer weight of debt the company still carries. Net financial liabilities stood at 32.5 billion euros at the end of the first quarter, and Bayer expects that figure could climb to 33 billion euros by year-end. Free cash flow turned deeply negative in the first quarter at minus 2.3 billion euros, compared with minus 1.5 billion a year earlier, driven by legal payouts of around 5 billion euros expected for 2026 as a whole. The debt burden is a structural drag that leaves little margin for error. Fitch Ratings underlined the concern in February when it revised Bayer’s outlook to negative while affirming the BBB long-term rating.
Should investors sell immediately? Or is it worth buying Bayer?
First-quarter results offered a bright spot on the earnings side. EBIT before special items rose 10.1% to 3.2 billion euros, and net income surged 113% to 2.8 billion euros. Yet these numbers mask the steady erosion of revenue from Xarelto, the blockbuster blood thinner whose patents are expiring; sales from the drug fell by a third in 2025 to $2.6 billion. Bayer is counting on Asundexian to fill that gap, but also on continued growth from Nubeqa and Kerendia in pharma and steady performance from the Crop Science division. A newly announced acquisition of Perfuse Therapeutics in June adds an ophthalmology pipeline that could diversify the portfolio further.
Alongside the balance-sheet constraints, new risks are emerging from Washington. Since June, the US has been conducting a trade investigation into German drug-pricing practices, raising the specter of tariffs on pharmaceutical imports. Such a move would directly hit Bayer’s pharma operations and is a risk that market participants have barely begun to price in. Meanwhile, CEO Bill Anderson has signaled that if legal certainty does not materialize, Bayer could abandon US glyphosate production entirely — a threat that underscores how far the company is willing to go to draw a line under the litigation legacy.
Some investors are pushing for a more radical response. A faction of shareholders sees value in breaking up the conglomerate, specifically spinning off the Monsanto agricultural business or pursuing a broader restructuring. Management, backed by new CFO Judith Hartmann, has so far resisted those calls, insisting that the current structure offers synergies. That tension between investor expectations and management’s stance is a recurring undercurrent that could resurface if the stock’s momentum stalls.
The immediate test is the Missouri settlement hearing on July 9. If the judge grants final approval, one of the two giant question marks hanging over Bayer will be replaced by a clear path to closure — at least on the glyphosate front. If the judge rejects it or imposes conditions, the uncertainty drags on and the rally’s logic weakens. After that date, attention shifts to second-quarter results, which will show whether the company can credibly manage its debt reduction targets while still burning through billions in legal cash. The Supreme Court win was real, but turning legal relief into a fundamental revaluation will require clean execution on the pipeline, a benign outcome in Missouri, and a market that is willing to look past a mountain of debt.
Ad
Bayer Stock: New Analysis - 30 June
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
